These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 37256916)

  • 1. Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.
    Williams LD; Shen X; Sawant SS; Akapirat S; Dahora LC; Tay MZ; Stanfield-Oakley S; Wills S; Goodman D; Tenney D; Spreng RL; Zhang L; Yates NL; Montefiori DC; Eller MA; Easterhoff D; Hope TJ; Rerks-Ngarm S; Pittisuttithum P; Nitayaphan S; Excler JL; Kim JH; Michael NL; Robb ML; O'Connell RJ; Karasavvas N; Vasan S; Ferrari G; Tomaras GD;
    PLoS Pathog; 2023 May; 19(5):e1011359. PubMed ID: 37256916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
    Easterhoff D; Moody MA; Fera D; Cheng H; Ackerman M; Wiehe K; Saunders KO; Pollara J; Vandergrift N; Parks R; Kim J; Michael NL; O'Connell RJ; Excler JL; Robb ML; Vasan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Liao HX; Ferrari G; Seaman MS; Montefiori DC; Tomaras GD; Harrison SC; Haynes BF
    PLoS Pathog; 2017 Feb; 13(2):e1006182. PubMed ID: 28235027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
    Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
    Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
    Akapirat S; Karnasuta C; Vasan S; Rerks-Ngarm S; Pitisuttithum P; Madnote S; Savadsuk H; Rittiroongrad S; Puangkaew J; Phogat S; Tartaglia J; Sinangil F; de Souza MS; Excler JL; Kim JH; Robb ML; Michael NL; Ngauy V; O'Connell RJ; Karasavvas N;
    PLoS One; 2018; 13(4):e0196397. PubMed ID: 29702672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
    Rerks-Ngarm S; Pitisuttithum P; Excler JL; Nitayaphan S; Kaewkungwal J; Premsri N; Kunasol P; Karasavvas N; Schuetz A; Ngauy V; Sinangil F; Dawson P; deCamp AC; Phogat S; Garunathan S; Tartaglia J; DiazGranados C; Ratto-Kim S; Pegu P; Eller M; Karnasuta C; Montefiori DC; Sawant S; Vandergrift N; Wills S; Tomaras GD; Robb ML; Michael NL; Kim JH; Vasan S; O'Connell RJ;
    J Infect Dis; 2017 Apr; 215(8):1255-1263. PubMed ID: 28329190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
    Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
    PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.
    Easterhoff D; Pollara J; Luo K; Tolbert WD; Young B; Mielke D; Jha S; O'Connell RJ; Vasan S; Kim J; Michael NL; Excler JL; Robb ML; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Wiehe K; Saunders KO; Montefiori DC; Tomaras GD; Moody MA; Pazgier M; Haynes BF; Ferrari G
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31776278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability.
    Shubin Z; Stanfield-Oakley S; Puangkaew J; Pitisutthithum P; Nitayaphan S; Gurunathan S; Sinangil F; Chariyalertsak S; Phanuphak N; Ake JA; O'Connell RJ; Vasan S; Akapirat S; Eller MA; Ferrari G; Paquin-Proulx D;
    AIDS; 2023 Aug; 37(10):1519-1524. PubMed ID: 37260254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
    Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
    PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial.
    Tolbert WD; Van V; Sherburn R; Tuyishime M; Yan F; Nguyen DN; Stanfield-Oakley S; Easterhoff D; Bonsignori M; Haynes BF; Moody MA; Ray K; Ferrari G; Lewis GK; Pazgier M
    mBio; 2020 Jun; 11(3):. PubMed ID: 32605979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response.
    Fischinger S; Shin S; Boudreau CM; Ackerman M; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Kim JH; Robb ML; Michael NL; O'Connell RJ; Vasan S; Streeck H; Alter G
    JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32554928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
    Moodie Z; Andersen-Nissen E; Grunenberg N; Dintwe OB; Omar FL; Kee JJ; Bekker LG; Laher F; Naicker N; Jani I; Mgodi NM; Hunidzarira P; Sebe M; Miner MD; Polakowski L; Ramirez S; Nebergall M; Takuva S; Sikhosana L; Heptinstall J; Seaton KE; De Rosa S; Diazgranados CA; Koutsoukos M; Van Der Meeren O; Barnett SW; Kanesa-Thasan N; Kublin JG; Tomaras GD; McElrath MJ; Corey L; Mngadi K; Goepfert P;
    PLoS Med; 2024 Mar; 21(3):e1004360. PubMed ID: 38502656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.
    Karnasuta C; Akapirat S; Madnote S; Savadsuk H; Puangkaew J; Rittiroongrad S; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Tartaglia J; Sinangil F; Francis DP; Robb ML; de Souza MS; Michael NL; Excler JL; Kim JH; O'Connell RJ; Karasavvas N
    AIDS Res Hum Retroviruses; 2017 May; 33(5):410-423. PubMed ID: 28006952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RV144 HIV-1 vaccination impacts post-infection antibody responses.
    Mdluli T; Jian N; Slike B; Paquin-Proulx D; Donofrio G; Alrubayyi A; Gift S; Grande R; Bryson M; Lee A; Dussupt V; Mendez-Riveria L; Sanders-Buell E; Chenine AL; Tran U; Li Y; Brown E; Edlefsen PT; O'Connell R; Gilbert P; Nitayaphan S; Pitisuttihum P; Rerks-Ngarm S; Robb ML; Gramzinski R; Alter G; Tovanabutra S; Georgiev IS; Ackerman ME; Polonis VR; Vasan S; Michael NL; Kim JH; Eller MA; Krebs SJ; Rolland M
    PLoS Pathog; 2020 Dec; 16(12):e1009101. PubMed ID: 33290394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
    Huang Y; Seaton KE; Casapia M; Polakowski L; De Rosa SC; Cohen K; Yu C; Elizaga M; Paez C; Miner MD; Kelley CF; Maenza J; Keefer M; Lama JR; Sobieszczyk M; Buchbinder S; Baden LR; Lee C; Gulati V; Sinangil F; Montefiori D; McElrath MJ; Tomaras GD; Robinson HL; Goepfert P;
    Vaccine; 2021 Jul; 39(33):4641-4650. PubMed ID: 34229888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
    Kim JH; Excler JL; Michael NL
    Annu Rev Med; 2015; 66():423-37. PubMed ID: 25341006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.